Nucleai has partnered with Sirona Dx to provide an integrated spatial proteomics solution for pharmaceutical and biotechnology firms for drug development.
Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.
Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.
The FDA's guidance emphasises the potential of NGS methods to mitigate safety risks associated with therapies incorporating genome editing.
Amazon has already collaborated with Memorial Sloan Kettering Cancer Center with its AI drug discovery software.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results